Bio-Technopark
In very close proximity to the Swiss Federal Institute of Technology (ETH), the University and Zurich University Hospital, a science park for life science companies and institutions has developed in the last two decades, which has now acquired both national and international significance. On the former site of the Schweizerische Wagons- und Aufzügefabrik AG and on neighboring sites, 100,000 m2 of laboratory, production and office space is now leased to around 60 companies and organizations, and 80 academic research groups. Video
Leasing
In the Bio-Technopark, it is possible to rent ultramodern laboratories, offices, and complex infrastructure for research and development purposes. The premises offered include fully-equipped laboratory facilities with partly shared infrastructure, and individual rental areas in different sizes and locations and with different fit-out standards. The Bio-Technopark is still being developed and gradually fitted out.
Services
The Bio-Technopark promotes the transfer of knowledge and technology, as well as the foundation and building up of life science companies. In addition to advice, coaching, and support for those who are setting up and developing companies and looking for financing, its services include the organization of events that focus on networking, facilitating the exchange of ideas between specialists, and advanced training.
News
Swiss Bioscience and OrganTech collaborating on hair regeneration
Schlieren/Tokyo - Swiss Bioscience, based in Schlieren in the canton of Zurich, and the biotech company OrganTech from Tokyo are exploring a strategic collaboration. This will involve the regulatory development, manufacturing and commercialization of OrganTech’s hair regeneration technologies by Swiss Bioscience. (CONNECT) OrganTech has selected Swiss Bioscienceas its preferred strategic partner...
CDR-Life Announces CDR209, a Novel T Cell Engager for Treatment of Axial Spondyloarthritis
ZURICH, Switzerland--(BUSINESS WIRE)--CDR-Life, Inc., a clinical-stage biotechnology company developing highly selective T cell engagers (TCEs) to treat cancer and autoimmune diseases, today announced its newest development candidate, CDR209, a novel T cell engager for the treatment of axial spondyloarthritis (axSpA) and potentially other HLA-B27 associated autoimmune diseases. "CDR209 represents an important...